NCT02524106 - Bococizumab HIV Evaluation (B-HIVE) Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions

DyslipidemiaCardiovascular Disease

Interventions

DRUG

Bococizumab

PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.

DRUG

Placebo

placebo

Trial Locations (3)

94110

San Francisco General Hospital, San Francisco

94115

Quest Clinical Research, San Francisco

94121

San Francisco Veteran's Affair Medical Center, San Francisco